Adverse events reports generated in DTC campaigns require "minimal information" collection -- PhRMA.
Executive Summary
ADVERSE EVENT REPORTS FROM DTC CAMPAIGNS REQUIRE "MINIMAL INFORMATION" to be collected from consumers by sponsors, the Pharmaceutical Research & Manufacturers of America suggests in a proposed approach to processing adverse event reports from consumers that are medically unconfirmed. When patients report adverse events in response to contacts made as part of a direct-to-consumer campaign, sponsors should collect "patient identification, the product, the adverse experience(s) and the reporter information," the PhRMA proposal states. The proposal was submitted in response to the International Conference on Harmonization draft guidance on periodic safety update reports for marketed products.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth